Seneca Growth Capital VCT
The Seneca Growth Capital VCT B share class was launched in May 2018. To date, the B share class has raised £8.7 million (December 2020).
Over the past year to January 2021, the VCT sold shares in three of its AIM holdings (one full and two partial sales), realising returns of between 1.6x – 2.2x. Past performance is not a guide to the future. The current portfolio consists of ten investee companies, three of which are quoted on AIM.
Despite being new, the Seneca Growth Capital VCT B Shares have paid a total of 6p in dividends since launch, with a further 1.5p due in May 2021 – dividends are variable and not guaranteed.
The VCT currently has net assets of £8.3 million, and approximately £4.5 million held in cash (December 2020). The current offer seeks to raise up to £10 million with an additional £10 million overallotment facility.
Read important documents and apply
- Raised £8.7 million since launching in 2018
- 54% of the VCT is held in cash
- The portfolio has ten holdings, three of which quoted on AIM
- Seneca is an experienced growth capital investor, now managing more than £60 million of VCT and EIS growth capital
- Management team has invested personally in the offer
- Available this tax year (2021/22)
- Minimum investment £3,000; you can apply online
The VCT is managed by Seneca Partners Limited. In 2018 it took over the management of Hygea vct plc, renamed it, and launched a new and separate B share class.
Although relatively new to the VCT market, Seneca is an experienced growth capital investor. It has raised and deployed more than £60 million of EIS and VCT growth capital into 50+ SME companies through over 100 funding rounds since 2010 (August 2020).
The Seneca Growth Capital VCT is managed by the same team behind Seneca’s EIS funds, including shareholder directors Richard Manley, Ian Currie, and Tim Murphy. All three are SME specialists by background. Their previous experience includes KPMG, NM Rothschild, Cenkos Fund Managers, Altium, Apax, RBS, Deloitte and HBOS.
Directors of Seneca and key members of the management team in the wider group of Seneca branded companies have committed to invest over £80k in the current offer, taking their total investment in the VCT to more than £380k.
Watch an interview with investment manager John Davies of Seneca Partners:
The VCT follows the same generalist investment strategy the manager has been applying to its EIS Portfolio Service. The VCT has benefitted and is expected to continue to benefit from the same deal flow, investment process and co-investment opportunities that come from Seneca's EIS activity.
Seneca believes this allows the VCT to participate in a higher number of investments of a larger scale into more established businesses than otherwise possible for a VCT of its size.
Seneca seeks well managed businesses with strong leadership teams that can demonstrate established and proven concepts in addition to growth potential. Businesses may be unquoted or AIM quoted. The team targets a 2x return on all investments – not guaranteed.
Exit track record
Over the past year to January 2021, the VCT sold shares in three of its AIM holdings (one full and two partial sales), realising returns of between 1.6x – 2.2x investment cost.
There have been no failures yet (the B Share class is still relatively new). However, failures are to be expected when investing in younger, smaller companies. Please remember past performance is not a guide to the future.
Genedrive plc is an AIM-quoted molecular diagnostics company developing and commercialising a low-cost, rapid, versatile, simple to use platform for the diagnosis of infectious diseases and pathogen detection and other indications.
In 2020 the business experienced rapid share price appreciation after announcing it would refocus its resources towards developing a Covid-19 test. In May 2020, the test kit received CE approval and became available for commercial sale across the European Union, including the UK.
The VCT initially invested £126k into the business. However, following a period of heightened volatility within the AIM market, Seneca decided to fully exit its investment in May 2020, realising a profit of £136k for the VCT. Past performance is not a guide to the future.
Following the outbreak of Covid-19, Seneca made a provision against the carrying value of three of its unquoted investments: SilkFred, Qudini, and Fabacus.
SilkFred is an online women’s fashion retailer, due to the perceived hit to discretionary consumer spending, the holding value of the investment was marked down by £250k. However, following a material recovery in the company’s trading performance, the provision was reduced to £125k and fully removed in December 2020.
Qudini is a SaaS business focused on providing software to the retail sector for appointment bookings, queue management and event management. The holding value has been marked down by 40%, or £200k.
Fabacus, a supply chain data intelligence platform, has had its holding value reduced by £64k, erasing previous unrealised gains.
The trust NAV was reduced by 12% to 79.5p and has since recovered to 99.4p (as at 19 February 2021 ) – please note, past performance is not a guide to the future.
Seneca expects to see an increase in the number of businesses seeking investment to support their growth plans over the next 12–18 months as a result of Covid-19. As at 31 December 2020, the B shares portfolio held £4.5 million in cash, equivalent to 54% of net assets. Seneca believes the VCT is well placed to support its investee companies and take advantage of new growth capital opportunities.
Current portfolio overview
The Seneca Growth Capital B Shares has net assets of £8.3 million, of which £4.5 million is held in cash (December 2020) . The investment portfolio consists of ten investee companies, three of which are AIM-quoted investments.
Examples of portfolio companies
SkinBioTherapeutics plc (AIM quoted, largest investment)
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
SkinBioTherapeutics targets three specific skin healthcare sectors: cosmetics, infection control and eczema. The most commercially advanced programme is focused on the application of the SkinBiotix® platform in managing sensitive skin in the cosmetics industry.
Seneca initially invested in SkinBioTherapeutics when it was admitted to AIM in April 2017. The VCT first invested in February 2019. The position was valued at £990k, on an investment cost of £721k (December 2020). The holding was partially sold in January 2021, generating a 2.2x return on investment cost. Past performance is not a guide to the future.
Ten80 Group Limited (recent investment)
Ten80 Group is a remote working platform and marketplace which connects its clients to a pool of consultants / freelancers.
The business was founded in 2019. By May 2020 it had a database of 150,000 customers and worked with corporates including Walmart, Limelight and OK!.
The majority of Ten80’s services are within a core SaaS product, charging an up-front license fee, as well as a commission percentage to both parties (client and contractor) for the work performed through the Ten80 platform. Ten80 effectively acts as a contractor recruitment and problem-solving platform, with the focus being on outcomes rather than the traditional time-based billing methods, making it much more simple and efficient. There is now an enhanced use case for the product to allow the business to continue working during the Covid-19 crisis.
Seneca has invested a total £500k – of which £400k through the B Shares in March 2020. The investment has allowed the business to expand its team from two founders to eleven employees, with plans to increase headcount to 40 by the end of 2020.
Performance and dividends
The VCT targets dividends of at least 3p per annum in relation to the B Shares with an ambition to increase this to c.5% per annum of the B Share NAV by 2023 (subject to B Share investment performance and an intention to maintain a relatively stable NAV per B Share).
The VCT has existing distributable reserves which may be used to facilitate the payment of dividends on the B Share class in the early years. The VCT paid 3p per B Share in total in FY 2019. Please note, dividends are variable and not guaranteed.
Please note, the portfolio is relatively small and, as the share class only launched in 2018, the track record is limited and so is diversification within the portfolio. As is to be expected with all growth capital businesses, investments can fail or be subject to sudden falls in value.
Source: Morningstar. Past performance is no guide to the future. Dividends are variable and not guaranteed. The bar chart shows net asset value and cumulative dividends per share for the period 31 Dec 2018 to 31 March 2021.
Source: Seneca. Dividends paid in calendar year. Dividends are not guaranteed and past performance is not a guide to the future.
This, like all investments available through Wealth Club, is only for experienced investors happy to make their own investment decisions without advice.
VCTs are high-risk so should only form part of a balanced portfolio and you should not invest money you cannot afford to lose. They also tend to be illiquid and hard to sell and value. Before you invest, please carefully read the Risks and Commitments and the offer documents to ensure you fully understand the risks.
Tax rules can change and benefits depend on circumstances.
VCTs can now only invest new money in growth capital deals. Management buyouts, replacement capital deals and investments in mature companies are no longer permitted. This results in considerably higher risks.
This is a relatively new VCT offering. Seneca’s expertise to date has largely been in EIS investments. If fundraising is slower than expected or does not reach its anticipated targets, there may be a delay in allotting shares, and fewer investments will be made overall.
There are two share classes: Ordinary (relating to the original Hygea VCT) and B ordinary shares. The interests of Ordinary and B Shareholders may not always be aligned.
Charges and savings
A summary of the main charges and savings is shown below. The net initial charge shown includes the Wealth Club saving and any early bird discount. The investment may have additional charges and expenses: please see the provider documents including the Key Information Document for more details.
Please note, capacity – for the offer or any early bird savings – can be reached early, and we may not be notified of this by the VCT in real time.
|Full initial charge||5.5%|
|Early bird discount||—|
|Wealth Club initial saving||4.5%|
|Existing shareholder discount||1%|
|Net initial charge through Wealth Club (new investors)||1%|
|Net initial charge through Wealth Club (existing shareholders)||0%|
|Annual management charge||2%|
|Annual administration charge||See details|
|Annual rebate from Wealth Club||0.20%|
More detail on the charges
- Deadline for investment in tax year 2021/22: 26 May 2021 (noon)
- Closing date of the offer: 28 May 2021 (5pm)
The board intends to buy back shares at up to a 5% discount to the prevailing net asset value. This is subject to availability and board and shareholder approval. Please see the offer documents for details.
Dividend Reinvestment Scheme (DRIS)
There is currently no Dividend Reinvestment Scheme. The company is currently considering launching a dividend reinvestment scheme in due course.
Annual rebate when you invest through Wealth Club
The VCT offer includes an annual rebate for Wealth Club investors, payable for the first three years. This is a rebate of our renewal commission and should be equivalent to 0.20% of the Net Asset Value of the Offer Shares issued to you when you invest. You will find the terms and conditions for annual rebates within our Terms of Business.
The VCT launched in 2018 and has since attracted £8.7 million from investors. The portfolio contains ten investee companies, three of which are AIM-quoted investments.
This is a recently launched share class within an existing VCT, its track record is limited. Despite seeing an initial decline in NAV in March 2020, as one might expect, the VCT has now more than fully recovered from the initial impact of the pandemic, with the NAV rising to 99.4p per share in February 2021, although as always, past performance is not a guide to the future.
Wealth Club aims to make it easier for experienced investors to find information on – and apply for – tax-efficient investments. You should base your investment decision on the provider's documents and ensure you have read and fully understand them before investing. This review is a marketing communication. It is not advice or a personal or research recommendation to buy the investment mentioned. It does not satisfy legal requirements promoting investment research independence and is thus not subject to prohibitions on dealing ahead of its dissemination.
- Target dividend
- Initial charge
- Initial saving via Wealth Club
- Net initial charge
- 1% (0% for existing shareholders)
- Annual rebate
- Funds raised / sought
- £4.6 million / £10.0 million
- 26 May 2021 (noon) for 2021/22 allotment